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Abstract
Purpose—To assess breast cancer screening utilization in Medicare beneficiaries with colorectal 
and lung cancer versus cancer-free controls.
Methods—Female fee-for-service Medicare beneficiaries who were ≥67 years old and diagnosed 
with lung or colorectal cancer between 2000 and 2011 and who reported to a Surveillance, 
Epidemiology, and End Results (SEER) registry (case group) were followed for 2 years after their 
diagnoses, unless death, a diagnosis of breast cancer, or the end of 2013 came first. A similar 
number of cancer-free controls were individually matched to cases by age, race, registry region, 
and follow-up time. Screening utilization was defined as the percentage of women with ≥1 
screening mammogram during follow-up.
Results—Overall, 104,164 cases (48% colorectal, 52% lung; 30% advanced cancer) and 104,164 
controls were included. Among women with lung or colorectal cancer, 22% underwent ≥1 
screening mammogram versus 26% of controls (odds ratio [OR] 0.80; 95% confidence interval 
[CI] 0.78–0.82). Stratified by cancer type, 28% of colorectal cancer cases versus 29% of controls 
(OR 0.98; 95% CI 0.95–1.01) and 17% of lung cancer cases versus 23% of controls (OR 0.63; 
95% CI 0.60–0.65) received ≥1 mammogram. When stratified by stage, 8% with advanced cancer 
versus 18% of controls (OR 0.33; 95% CI 0.31–0.35) and 30% with early-stage cancer versus 30% 
of controls (OR 1; 95% CI 0.97–1.02) underwent ≥1 mammogram.
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Conclusion—Screening mammography utilization rates are similar between Medicare 
beneficiaries with early-stage cancer versus controls. Although the majority of patients with 
advanced-stage cancer appropriately do not pursue screening mammography, a small number (8%) 
continue with screening.
Keywords
Screening mammography; cancer survivorship period; utilization; population-based
INTRODUCTION
Advances in early cancer detection and treatment have led to an approximate 20% decrease 
in mortality between 1991 and 2010 [1]. In general, cancer survivors are at increased risk of 
developing second primary malignancies [2] from genetic syndromes, shared etiologic 
factors, or late sequel of treatment. These second malignancies account for 16% of all cancer 
diagnoses [3]. Lung and colorectal cancer survivorship, however, does not seem to increase 
the risk of subsequent breast cancer [4–6]. Accordingly, breast cancer screening rates in 
survivors of early-stage lung and colorectal cancer are expected to be similar to those in a 
cancer-free population. However, life expectancy of cancer survivors varies by disease stage. 
Routine screening may not benefit those presenting with advanced cancer, driving 
unnecessary health care costs [7].
The utilization of cancer screening tests during cancer survivorship is multifactorial and 
involves considerable discretion by the treating physician [8], who needs to assess the 
patient’s life expectancy and communicate that prognosis to the patient. Sometimes, 
screening tests are performed at patients’ requests, even if contrary to guidelines. Patients 
sometimes use their primary cancer diagnosis as a behavior-changing event or use denial as 
a coping strategy [7,9]. Furthermore, variation and uncertainty exist among health care 
practitioners about the best use of cancer screening in patients with existing cancer 
diagnoses.
Studies from over two decades ago reported a slight but not significant increase in screening 
mammography utilization in colorectal cancer survivors after their cancer diagnosis [10,11]. 
Considerable interval changes in breast cancer screening utilization overall [12–15], breast 
cancer screening guidelines [16,17], increased breast cancer awareness [18], and decreased 
mortality of cancer survivors [1] warrants a re-evaluation of the rate, frequency, and interval 
of screening mammography utilization in the broad population of patients with a new cancer 
diagnosis (compared with a cancer-free population). In addition to understanding 
contemporary rates of screening utilization, information about the distribution of screening 
utilization by stage at diagnosis could guide initiatives to ensure more appropriate screening.
The purpose of this study was to compare utilization rates of breast cancer screening in 
women 67 years or older with a new diagnosis of colorectal or lung cancer to screening rates 
(1) in a cancer-free Medicare control group and (2) in the same patients in the 2 years before 
their primary cancer diagnosis. We further compared utilization rates for individuals with 
late- versus early-stage diagnoses and then explored predictors of screening mammography 
within the case population.
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METHODS
Institutional Review Board approval and a waiver of informed consent were both obtained 
for this HIPAA-compliant retrospective review of linked Surveillance, Epidemiology, and 
End Results (SEER) Program and Medicare carrier claims data.
Data Source
We used SEER-Medicare, a cancer registry and claims-based database of medical care 
received by Medicare beneficiaries with cancer. The database includes SEER program 
information from cancer registries in 13 states or metropolitan areas (18 registries covering 
approximately 28% of the US population) and fee-for-service claims for covered health care 
services (both Parts A and B benefits) for all SEER registry Medicare beneficiaries from the 
time of a person’s Medicare eligibility until death [19,20]. The linkage of SEER with 
Medicare data used for this study was last updated in 2014 [19].
Study Population
Cancer Cases—All Medicare-enrolled women 67 years or older registered in SEER 
between 2000 and 2011 with a diagnosis of colorectal or lung cancer were assessed for 
eligibility. These specific cancers were selected because they represent the most common 
nonbreast malignancies in women [21]. We excluded all patients in whom colorectal or lung 
cancer was not their first primary cancer, as well as those with an unknown month of cancer 
diagnosis, a diagnosis reported only from autopsy or death certificate, a date of death before 
date of diagnosis, or a death or breast cancer diagnosis within the first 3 months after the 
colorectal or lung cancer diagnosis. To ensure complete claims capture, we only included 
patients continuously enrolled in Medicare Parts A and B and not enrolled in a Medicare 
HMO from 2 years before cancer diagnosis to a follow-up end date defined as 2 years and 3 
months after diagnosis, a diagnosis of breast cancer, death, or the censoring date of 
December 31, 2013, whichever came first. We defined patients with advanced cancer as 
those with SEER-derived American Joint Committee on Cancer (AJCC) [22] stage IV 
colorectal cancer and IIIB-IV lung cancer, which have an estimated overall 5-year survival 
of 5% and 3%, respectively [7].
Cancer-Free Controls—A matched cohort of female fee-for-service Medicare enrollees 
without cancer with sufficiently complete demographic information was identified from a 
random 5% sample of Medicare fee-for-service beneficiaries residing in SEER areas. Each 
cancer patient was individually matched to a cancer-free control by birth year, race, and 
registry region. As with cancer cases, we only included controls continuously enrolled in 
Medicare Parts A and B between the date of the corresponding case diagnosis and case 
follow-up end date. Each control had exactly the same amount of follow-up time as her 
corresponding cancer case.
Screening Mammography Utilization
We restricted the analysis to billing codes that specifically identify screening (rather than 
diagnostic) mammography. Screening mammography services were identified using Current 
Procedural Terminology (CPT) codes 77057 and 76092 and Healthcare Common Procedure 
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Coding System (HCPCS) codes G0202 and G0203 [23]. All duplicate claims were 
eliminated by matching patient identifier, examination date, and CPT or HCPCS code.
Screening utilization rates were defined as the percentage of women undergoing at least one 
screening mammogram between follow-up start and end dates. To help ensure a screening 
mammogram was not part of a colorectal or lung cancer diagnosis workup, the follow-up 
start date was defined as 3 months after cancer diagnosis for all study outcomes and 
extended for a maximum of 2 years beyond that date.
Study Outcomes
The primary outcome was the utilization of screening mammography in Medicare 
beneficiaries with colorectal and lung cancer versus a cancer-free control group between the 
follow-up start and end dates. We further performed time to event analysis to estimate 
screening rates over time.
A secondary outcome was the utilization of screening mammography in Medicare 
beneficiaries with colorectal or lung cancer within 2 years before versus 2 years after 
diagnosis.
Statistical Analysis
Screening mammography utilization was compared using McNemar’s test for cancer cases 
versus cancer-free controls (primary outcome) and before versus after cancer diagnosis 
(secondary outcome). Odds ratios (ORs) were calculated using the Mantel-Haenszel method 
for matched pairs [24]. A time to event analysis was further performed for the primary 
outcome by plotting the cumulative incidence of a screening event over a 2-year window 
after diagnosis for cases and controls. Estimated screening event rates and 95% confidence 
intervals (CIs) over time are reported.
Predictors of screening mammography utilization among cases was assessed using 
multivariable logistic regression analyses, modeling cancer site (lung, colon), stage (0-IV), 
age at diagnosis (65–69 years, 70–74 years, 75–79 years, >80 years), race or ethnicity 
(white, African American, other), geographic region (Northeast, Southeast, Midwest, West), 
marital status (married, not married), and SEER poverty index (0%–<5%, 5%–<10%, 10%–
<20%, 20%–100%). Multicollinearity was checked using variance inflation factors.
Statistical analyses were conducted using SAS version 9.2 (SAS Institute Inc, Cary, North 
Carolina, USA). All significance tests were two-sided and used a 5% level of significance.
RESULTS
Study Population Characteristics
Overall, 104,164 cancer cases and 104,164 matched controls were included for the primary 
outcome analysis (Fig. 1). Baseline characteristics of cancer cases are shown in Table 1. 
Forty-eight percent of patients had colorectal and 52% had lung cancer. Mean age at 
diagnosis was 78 (standard deviation 7), ranging from 67 to 107, and did not vary 
remarkably by cancer site; 87% of patients were white and 35% were married. By study 
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design, selected demographics (age, race, and region) of control cases mirrored those of 
cancer cases.
Utilization of Screening Mammography in Cases Versus Controls
Utilization of screening mammography is shown in Table 2. Among women with newly 
diagnosed colorectal or lung cancer, 22% underwent at least one screening mammogram 
versus 26% of controls (OR 0.80; 95% CI 0.78–0.82) within the 2-year follow-up window. 
Stratified by cancer type, 28% of colorectal cancer cases versus 29% controls (OR 0.98; 
95% CI 0.95–1.01) and 17% of lung cancer cases versus 23% controls (OR 0.63; 95% CI 
0.60–0.65) received at least one mammogram. When further stratified by stage of the case, 
8% with newly diagnosed advanced cancer versus 18% of controls (OR 0.33; 95% CI 0.31–
0.35) and 30% with newly diagnosed early-stage cancer versus 30% of controls (OR 1; 95% 
CI 0.97–1.02) underwent at least one mammogram.
Appendix 1 and Figure 2 show time to event analysis for screening mammography rates at 6, 
12, 18, and 24 months within the 2-year follow-up window. Screening rates in cancer 
patients are slightly lower than controls regardless of time interval. This gap in event rates is 
higher in lung cancer patients, but very minimal in colorectal cancer patients. In advanced 
cancer patients, the screening rate difference between cases and controls increases over time. 
In early-stage cancer, the difference is minimal and does not change over time.
Utilization of Screening Mammography Changes Before and After Cancer Diagnosis
Receipt of at least one screening mammogram within 2 years after diagnosis of colorectal or 
lung cancer compared with 2 years before diagnosis was 22% versus 38% (OR 0.28; 95% CI 
0.27–0.29). Stratified by cancer type, this was 28% versus 35% for colorectal (OR 0.59; 
95% CI 0.57–0.61) and 17% versus 42% for lung cancer patients (OR 0.13; 95% CI 0.13–
0.14). When stratified by stage, only 8% of patients with newly diagnosed advanced cancer 
received a screening mammogram within 2 years after diagnosis versus 40% within 2 years 
before diagnosis (OR 0.05; 95% CI 0.05–0.06). In comparison, 30% with newly diagnosed 
early-stage cancer received a screening mammogram within 2 years after diagnosis as 
opposed to 39% within 2 years before diagnosis (OR 0.48; 95% CI 0.47–0.50; Table 2).
Independent Predictors of Screening Mammography
Independent predictors of screening mammography are shown in Appendix 2. Higher 
screening mammography utilization within 2 years after cancer diagnosis was associated 
with colorectal compared with lung cancer (OR 2), lower AJCC stage (OR 4 for occult 
cancer, OR 8.1 for stage I, OR 4.3 for II, and OR 3.3 for III when compared with stage IV), 
younger age (OR 3.6 for <70; OR 3.1 for 70–74; OR 2.3 for 75–80 when compared with age 
> 80), white race (OR 1.2 compared with African American), being married (OR 1.5), lower 
poverty (OR 1.5 for poverty index <5%; OR 1.4 for index 5%–<10%; OR 1.1 for index 
10%–<20% when compared with index 20%–100%), and geography (OR 1.2 for Southeast 
and West when compared with Northeast; all P < .05). Except for race and geography, 
similar independent predictors were identified when analyses were performed for colorectal 
and lung cancer.
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DISCUSSION
In this study of screening mammography in fee-for-service Medicare beneficiaries with 
colorectal and lung cancer, cancer patients have slightly lower utilization rates compared 
with a cancer-free control population. In early-stage cancer patients, this difference is 
minimal. In patients with advanced cancer, utilization rates drop significantly over time 
compared with control patients. Nonetheless, 8% continue screening mammography, despite 
low 5-year survival likelihoods (5% for colorectal cancer and 3% for lung cancer) [7].
Prior studies have shown that some cancer survivors remain preoccupied about their health 
[25] and make positive health-protective changes (eg, adherence to follow-up tests and 
visits) and health-promoting behavior (eg, smoking cessation, healthy diet, exercise) after 
cancer diagnoses [25–28]. This preoccupation could also result in a desire for increased 
screening, even when additional cancer risk is not present. For example, overutilization of 
Pap smear screening was reported among women who have undergone hysterectomy [29]. 
Interestingly, among early-stage cancer survivors, we did not show increased screening rates, 
compared with matched cancer-free controls. Furthermore, when screening rates were 
compared with the same patient’s utilization of screening mammogram before her cancer 
diagnosis, utilization slightly decreased, which could be partly due to aging or death in the 
cases postdiagnosis, resulting in a shorter window for utilization assessment. Re-analyses of 
breast cancer screening utilization among early cancer patients should be conducted as 
additional SEER data become available to assess whether breast cancer screening continues 
to be appropriate in the late survivorship period.
In advanced cancer patients, screening rates were significantly lower than in a cancer-free 
population, and those rates diverged over time. Furthermore, screening rates after cancer 
diagnoses dropped significantly compared with patients’ prediagnosis screening rates. Both 
are likely mainly due to the predicted decreased survival as a result of advanced cancer, 
resulting in a median follow-up time of 6 months. Although the majority of advanced-stage 
cancer patients (92%) appropriately do not pursue screening mammography, a small 
proportion may continue to undergo screening mammography. Both the Society of Breast 
Imaging and the ACR recommend cessation of breast cancer screening in women with life 
expectancies shorter than 5 to 7 years [30]. A definitive explanation for our results cannot be 
gleaned from our retrospective analysis, but a variety of factors could be contributing. 
Ongoing screening in some advanced cancer patients might be due to fear of another cancer 
(enhancing their desire for screening even in the absence of evidence of potential benefit), 
denial of their primary cancer prognosis, using their primary cancer diagnosis as a behavior-
changing event [7,9], or inadequate communication about life expectancy and the lack of 
screening benefit with referring physician [8].
Our results are thus consistent with prior reports of screening mammography rates ranging 
from 9% among Medicare beneficiaries with advanced cancers and median survival of less 
than 2 years [7] to 34% in National Health Institute Survey participants with more than 75% 
risk of mortality within 5 years, regardless of prior cancer [31]. Therefore, age alone is 
insufficient in determining appropriateness of screening [31]. However, whether guideline 
changes are sufficient to improve appropriate screening utilization is unclear. There are 
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several reports of screening mammography utilization among women older than 75 years 
[32] despite lack of evidence for screening benefit and the possibility of overdiagnosis and 
overtreatment [17]. Both patients and referring physicians likely play a role in the choice to 
continue screening [33]. For many patients, screening cessation was seen as a major decision 
but continuing screening was not, and a physician’s recommendation to stop screening may 
in fact threaten patient trust [34]. For these reasons, referring physician surveys have shown 
that discussions about screening discontinuation can be uncomfortable and time-consuming 
[35].
The utilization of cancer screening in patients with short life expectancies could cause net 
harm to both the patients and their family or caregivers due to complications from 
subsequent diagnostic procedures, overtreatment of clinically unimportant cancers, 
psychological stress associated with overdiagnosis of a cancer that will not cause death or 
symptoms, and possibly temporary anxiety associated with false-positive results [32,36]. 
Studies estimate that 1 in 15 screening mammograms are false-positives [32,37] and 1 in 3 
breast cancers detected are overdiagnosed [38]. For individuals with advanced cancer and 
short life expectancies, additional diagnostic workup, whether it ends up being a false-
positive or true cancer that would likely never become clinically significant within 5 years, 
probably represents wasteful care and can also potentially result in psychological stress [39] 
in a patient with an already established cancer diagnosis.
Finally, cancer screening in patients with short life expectancies has health resource 
implications. More than 25% of Medicare dollars are spent at the end of life [40], and cancer 
consumes a great proportion of overall Medicare expenditures [41], with a 1- to 3-fold 
increase in monthly health care utilization rates starting from 3 to 5 months before a cancer 
diagnosis [42]. Mean 5-year net health care costs for Medicare-covered women with 
colorectal cancer have been estimated as $35,000 [43]. Furthermore, there are indirect costs 
associated with cancer screening and follow-up visits, such as cost of transportation to and 
from medical appointments, work absence and lost productivity, and child care coverage 
[44]. One strategy in limiting health care cost is to systematically identify unnecessary care 
that does not provide meaningful benefit [7]. Identification of wasteful care is challenging 
because each patient’s circumstances are unique, making it difficult to reliably define 
episodes of overuse [7]. Although costs are rarely the sole reason that guidelines set limits 
on screening [36], in cancer patients with short life expectancies, overscreening, 
overdetection, and overtreatment are examples of care unlikely to provide net benefit to 
patients. A more thoughtful decision to screen will likely partially reduce the costs of care in 
cancer patients.
When stratified by cancer type, we found that overall women with colorectal cancer are 
more likely to undergo screening mammography than those with lung cancer. This is likely 
partially due to later stages of cancer at diagnosis among patients with lung cancer compared 
with colorectal cancer. However, after adjusting the utilization based on staging and other 
patient demographics, screening mammography use remained 2-fold higher in colorectal 
cancer patients. As expected, factors associated with longer survival (such as younger age 
and lower AJCC stage) were associated with higher utilization rates of screening 
mammography. Furthermore, the sources of screening disparity among cancer survivors 
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were similar to the general population, namely, race [45], marital [46] and economic status 
[47], as well as geography [45].
This study has several limitations due to use of the SEER-Medicare data source. First, 
screening mammography use was determined using CPT or HCPCS billing codes for 
screening mammography. Some studies suggest underestimation of screening 
mammography rates when solely using screening mammography codes, with uncertainty in 
distinguishing screening from diagnostic mammograms [48]. To avoid overestimating 
screening mammography utilization, this study thus focused only on screening billing codes. 
Second, the overall screening mammography rate is lower compared with other studies with 
younger mean age population [49,50], probably because it included only Medicare 
beneficiaries 67 years and older. Finally, although 8% of advanced cancer patients continue 
to undergo screening mammography, it is unclear what proportion are among the small 
percentage of advanced cancer patients surviving beyond the recommended 5 years for 
screening mammography by societal guidelines.
CONCLUSION
In summary, the study results show that although there is no difference in screening 
mammography utilization among women with early-stage cancer versus cancer-free 
controls, 8% of women with advanced cancer continue screening mammography after their 
diagnosis compared with 18% in a cancer-free control matched on follow-up time and 40% 
of women within 2 years before diagnosis. Furthermore, women with colorectal cancer 
(compared with lung cancer) and certain sociodemographic characteristics are more likely to 
undergo screening mammography. Identifying areas of potential inappropriate utilization 
could help target interventions to improve clinical practice. Efforts should be made in 
ensuring appropriate utilization of screening mammography in the small proportion of 
advanced cancer patients who undergo this test, based on their individual survival rates and 
response to therapy. Such information about screening test utilization in cancer patients with 
short life expectancy could guide cancer screening guidelines and Medicare coverage 
decisions to reduce the costs of cancer care.
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Appendix 1
Time to event analysis for screening mammography in cases and control patients
Both Cancers Colorectal Cancer Lung Cancer
Case Ctrl Case Ctrl Case Ctrl
All stages
 6 months 11.1 (10.9–11.3)   15.3 (15–15.5)   12.7 (12.4–13)   14.7 (14.4–15.1) 9.5 (9.2–9.8) 15.9 (15.6–16.3)
 12 months 23.9 (23.6–24.3) 27.9 (27.6–28) 26 (25.6–26.5)   27 (26.6–27.4)   21.4 (21–21.9) 29.1 (28.6–29.6)
 18 months 29.8 (29.5–30.1) 33 (32.7–33.4) 31.7 (31.3–32.2) 31.9 (31.4–32.3) 27.6 (27–28.1) 34.6 (34–35.1)
 24 months 34 (33.7–34.4) 36.3 (36–36.7) 35.7 (35.2–36.2) 35.2 (34.7–35.7) 32.2 (32.6–32.8) 37.9 (37.4–38.5)
Advanced stage (stage IV colorectal and stage IIIB-IV lung cancer)
 6 months 5.4 (5–5.7) 15.4 (14.9–16) 4.4 (3.9–5.1) 14.9 (13.9–16) 5.6 (5.3–6) 16 (15.4–16.6)
 12 months 12.9 (12.3–13.5) 27.9 (27.1–28.7) 11.6 (10.6–12.7) 27.1 (25.6–28.5) 12.8 (12.1–13.5) 29.2 (28.3–31.2)
 18 months 17.5 (16.7–18.3) 32.4 (31.5–33.3) 15.5 (14.2–16.8) 31.5 (29.8–33.1) 17.1 (16.2–18) 34.3 (33.2–35.3)
 24 months 21.1 (20.2–22.1) 35.7 (34.7–36.7) 19.1 (17.6–20.7) 35 (33.2–36.8) 20.8 (16.7–21.9) 37.6 (36.4–38.7)
Early stage
 6 months 13.9 (13.6–14.2) 15.2 (14.9–15.5) 13.9 (13.6–14.3) 14.9 (14.5–15.2)   12.5 (12.1–12.9)   16.1 (15.6–16.6)
 12 months 28.2 (27.8–28.7) 27.9 (27.5–28.3) 27.9 (27.5–28.4) 27.3 (26.8–27.7) 26.7 (26–27.3) 29.5 (28.8–30.1)
 18 months 34.4 (33.9–34.8) 33.1 (32.7–33.6) 33.7 (33.3–34.2) 32.2 (31.7–32.7) 33.6 (32.9–34.3) 35.2 (34.5–35.9)
 24 months 38.5 (38–39) 36.5 (36.1–37) 37.7 (37.2–38.2) 35.5 (35–36) 38.4 (37.7–39.2) 38.6 (37.9–39.3)
Cumulative screening rates at each time point are shown in percentage and 95% confidence intervals. Ctrl = control.
Appendix 2
Independent predictors of screening mammography in patients with newly diagnosed 
colorectal or lung cancers within 2 years after diagnosis
Both Cancers, OR (95% 
CI)
Colorectal Cancer, OR 
(95% CI)
Lung Cancer, OR (95% CI)
Cancer type
 Colorectal vs lung 2 (2–2.1)
(P < .001)
NA NA
AJCC staging (reference “stage 4”)
 0 4 (3.8–4.4)
(P < .001)
6 (5.3–6.6)
(P < .001)
2.6 (2.3–2.9)
(P < .001)
 1 8.1 (7.6–8.6)
(P < .001)
8 (7.2–8.8)
(P < .001)
8.8 (8.2–9.4)
(P < .001)
 2 4.3 (4.1–4.6)
(P < .001)
5.5 (5–6)
(P < .001)
3.4 (3.1–3.7)
(P < .001)
 3 3.3 (3.1–3.5)
(P < .001)
4.7 (4.2–5.2)
(P < .001)
2.4 (2.2–2.7)
(P < .001)
Age (reference “age > 80”)
 65–69 3.6 (3.4–3.8)
(P < .001)
4.2 (3.9–4.5)
(P < .001)
2.8 (2.6–3)
(P < .001)
 70–74 3.1 (3–3.2) 3.6 (3.3–3.8) 2.4 (2.2–2.6)
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Both Cancers, OR (95% 
CI)
Colorectal Cancer, OR 
(95% CI)
Lung Cancer, OR (95% CI)
(P < .001) (P < .001) (P < .001)
 75–79 2.3 (2.2–2.4)
(P < .001)
2.4 (2.3–2.6)
(P < .001)
1.9 (1.8–2.1)
(P < .001)
Marital status (reference “not married”)
 Married 1.5 (1.5–1.6)
(P < .001)
1.5 (1.5–1.6)
(P < .001)
1.5 (1.4–1.6)
(P < .001)
Race (reference “African American”)
 White 1.2 (1.1–1.2)
(P < .001)
1.3 (1.2–1.4)
(P < .001)
1 (0.9–1.1)
(P .62)
 Other 1 (0.9–1.1)
(P = .41)
0.9 (0.8–1.1)
(P = .49)
1 (0.8–1.1)
(P = .66)
Poverty index (reference “20–100%”)
 0%–<5% 1.5 (1.4–1.6)
(P < .001)
1.5 (1.4–1.6)
(P < .001)
1.5 (1.4–1.7)
(P < .001)
 5%–<10% 1.4 (1.2–1.4)
(P < .001)
1.4 (1.3–1.5)
(P < .001)
1.3 (1.2–1.5)
(P < .001)
 10%–<20% 1.1 (1.1–1.2)
(P < .001)
1.2 (1.1–1.3)
(P < .001)
1.1 (1–1.2)
(P = .009)
SEER Registry (reference “Northeast”)
 Midwest 1 (1–1.2)
(P = .43)
1.1 (1–1.2)
(P < .001)
0.9 (0.8–1)
(P = .01)
 Southeast 1.2 (1.2–1.3)
(P < .001)
1.4 (1.3–1.5)
(P < .001)
1 (1–1.1)
(P = .36)
 West 1.2 (1.2–1.3)
(P < .001)
1.3 (1.2–1.4)
(P < .001)
1.1 (1–1.2)
(P = .02)
AJCC = American Joint Committee on Cancer; CI = confidence interval; OR = odds ratio; SEER = Surveillance, 
Epidemiology, and End Results.
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TAKE-HOME POINTS
▪ There is appropriate utilization of screening mammography among early-
stage cancer survivors.
▪ Eight percent of women with advanced cancer and short life expectancy 
continue screening mammography after their diagnosis compared with 18% 
in a matched cancer-free control and 40% of women within 2 years before 
diagnosis.
▪ Higher screening mammography utilization was associated with colorectal 
compared with lung cancer, lower AJCC stage, younger age, white race, 
being married, and more favorable economic status.
▪ The utilization of cancer screening in patients with short life expectancies has 
health resource implications and could cause net harm to patients due to 
complications from subsequent diagnostic procedures, overdiagnosis, and 
overtreatment.
▪ Identifying potential areas of overutilization may help target interventions to 
reduce low-yield care.
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Fig 1. 
Study flowchart for primary outcome analysis. CRC = colorectal cancer; DoD = date of 
death; Dx = diagnosis; SEER = Surveillance, Epidemiology, and End Results.
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Fig 2. 
Plots showing time to event analysis for screening mammography in cases (continuous line) 
and control (interrupted line) patients for (a) all patients, (b) advanced cancer patients, (c) 
early-stage cancer patients, (d) colorectal cancer patients, and (e) lung cancer patients.
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Table 1
Baseline characteristics of cancer cases
Characteristics* Both Cancers (N = 104,164) Colorectal Cancer (N = 50,432) Lung Cancer (N = 53,732)
Age at diagnosis, y (SD) 78 (7) 79 (7) 76 (6)
Race, N (%)
 White 90,492 (87) 43,124 (85) 47,368 (88)
 Black 8,356 (8) 4,372 (9) 3,984 (7)
 Other 5,316 (5) 2,936 (6) 2,380 (5)
Marital status, N (%)
 Married 34,551 (35) 16,384 (34) 18,167 (35)
 Not Married 64,897 (65) 31,478 (66) 33,419 (65)
SEER registry, N (%)
 Northeast 24,113 (23) 12,329 (25) 11,784 (22)
 Midwest 23,284 (22) 11,058 (22) 12,226 (23)
 Southeast 35,296 (34) 16,292 (32) 19,004 (35)
 West 21,471 (21) 10,753 (21) 10,718 (20)
Poverty index, N (%)
 0–<5% 27,019 (26) 13,222 (26) 13,797 (26)
 5–<10% 28,595 (28) 13,875 (28) 14,720 (27)
 10–<20% 29,129 (28) 13,994 (28) 15,135 (28)
 20–100% 19,138 (18) 9,182 (18) 9,956 (19)
AJCC staging, N (%)
 0 or occult 9,269 (10) 5,203 (11) 4,066 (8)
 1 21,988 (23) 10,643 (22) 11,345 (24)
 2 24,541 (25) 17,668 (37) 6,873 (14)
 3 15,983 (17) 7,499 (16) 8,484 (18)
 4 24,117 (25) 6,625 (14) 17,492 (36)
Advanced stage cancer,† N (%)
 Yes 28,669 (30) 6,625 (14) 22,044 (46)
 No 67,120 (70) 41,013 (86) 26,107 (54)
AJCC = American Joint Committee on Cancer; SD = standard deviation; SEER = Surveillance, Epidemiology, and End Results.
*
There were missing data for variables marital status, poverty, AJCC staging, and presence of advanced-stage cancer.
†
Advanced-stage cancer includes stage IV colorectal cancer and stage IIIB-IV lung cancer.
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